View in EDS PDF Full Text

High resolution molecular and histological analysis of renal disease progression in ZSF1 fa/faCP rats, a model of type 2 diabetic nephropathy.

Saved in:
Bibliographic Details
Title: High resolution molecular and histological analysis of renal disease progression in ZSF1 fa/faCP rats, a model of type 2 diabetic nephropathy.
Authors: Dower K; Inflammation and Immunology, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., Zhao S; Clinical Bioinformatics, Early Clinical Development, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., Schlerman FJ; Inflammation and Immunology, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., Savary L; Drug Safety, Pfizer Worldwide Research and Development, Andover, Massachusetts, United States of America., Campanholle G; Inflammation and Immunology, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., Johnson BG; Inflammation and Immunology, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., Xi L; Clinical Bioinformatics, Early Clinical Development, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., Nguyen V; Drug Safety, Pfizer Worldwide Research and Development, Andover, Massachusetts, United States of America., Zhan Y; Drug Safety, Pfizer Worldwide Research and Development, Andover, Massachusetts, United States of America., Lech MP; Inflammation and Immunology, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., Wang J; Inflammation and Immunology, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., Nie Q; Drug Safety, Pfizer Worldwide Research and Development, Andover, Massachusetts, United States of America., Karsdal MA; Nordic Bioscience A/S, Herlev, Denmark., Genovese F; Nordic Bioscience A/S, Herlev, Denmark., Boucher G; Drug Safety, Pfizer Worldwide Research and Development, Groton, Connecticut, United States of America., Brown TP; Drug Safety, Pfizer Worldwide Research and Development, Groton, Connecticut, United States of America., Zhang B; Clinical Bioinformatics, Early Clinical Development, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., Homer BL; Drug Safety, Pfizer Worldwide Research and Development, Andover, Massachusetts, United States of America., Martinez RV; Inflammation and Immunology, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America.
Source: PloS one [PLoS One] 2017 Jul 26; Vol. 12 (7), pp. e0181861. Date of Electronic Publication: 2017 Jul 26 (Print Publication: 2017).
Publication Type: Journal Article
Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1932-6203
DOI:10.1371/journal.pone.0181861